Merry Life Biomedical Company, Ltd. (Merry Life/MLB) is committed to the development for the treatment of Alzheimer’s disease. We focus on global development of new medication based on unique patent portfolio, rigorous research efforts and professional management, moving toward the ultimate solution for the Alzheimer’s disease. Today in the 21st century, the sheer number of dementia population and Alzheimer’s disease patients has become tremendous burden on the society, but we are still struggling to come up with a successful new medicine despite years of efforts that the medical society has made. Thanks to the high-tech platform under our professional team, Merry Life has obtained TML-6 and secured its exclusive licensing, a rare and encouraging opportunity.

　　Merry Life has now completed the pre-clinical study after four years of new drug development from 2019 to 2023. US FDA has approved IND in June 2024, and conducted new drug Phase I clinical trial in the U.S. in July 2024. TML-6 will be the new era bellwether in the new medical treatments for the Alzheimer's disease around the world, and we are willing and ready to take on the daunting challenge and complete our mission.